Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE Further subtype analysis of TNBCs showed the highest amplification rate (42%) in the basal-like 1 subtype and the lowest amplification rate (9%) in the luminal androgen receptor subtype. 26172299 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. 29484502 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE We identified and confirmed four distinct TNBC subtypes: (i) luminal androgen receptor (AR; LAR), (ii) mesenchymal (MES), (iii) basal-like immunosuppressed (BLIS), and (iv) basal-like immune-activated (BLIA). 25208879 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The androgen receptor (AR) is proposed as a therapeutic target for AR-positive advanced triple-negative breast cancer. 29713287 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Targeting androgen receptor (AR) in TNBC is thought to be a promising approach. 29964098 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. 30783520 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE SARMs may provide promise as novel targeted therapies to treat AR-positive triple-negative breast cancer. 25072326 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients' prognosis. 31319547 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Studies have shown that androgen receptor (AR) signaling activation may be one of the mechanisms, and targeting AR showed some promising results in AR-positive triple-negative breast cancer. 31434793 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. 30279965 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. 28194662 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Additionally, the presence of PIK3CA mutations of cfDNA was significantly correlated with positive androgen receptor phosphorylated form depending on PI3K signaling pathway (pAR) which is independent favorable prognostic factors of TNBC. 26353837 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We demonstrated that combination of AR antagonist (bicalutamide) and PARP inhibitor (ABT-888) could inhibit cell viability and induce cell apoptosis significantly whatever in vitro or in vivo setting in AR-positive TNBC. 27994514 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Early data from clinical trials evaluating AR antagonists in invasive/metastatic triple-negative breast cancer suggest that some patients may benefit from androgen blockade. 29489512 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE To further substantiate our hypothesis and provide mechanistic insights, we also looked at the expression and regulation of these factors in publically available microarray data and in a panel of TNBC AR-positive cell lines. 24715382 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Numerous experimental approaches are under way, and several encouraging drug classes, such as immune checkpoint inhibitors, poly(ADP-ribose) polymerase inhibitors, platinum agents, phosphatidylinositol-3-kinase pathway inhibitors, and androgen receptor inhibitors, are being investigated in TNBC. 27401886 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Studies have shown it to antagonize estrogen receptor alpha (ERα) DNA binding, thereby preventing pro-proliferative gene transcription; whilst others have demonstrated AR to take on the mantle of a pseudo ERα particularly in the setting of triple negative breast cancer. 30416486 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Recent efforts aimed at molecular characterisation of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins. 29202431 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE A poor DFS was observed for AR+/FOXA1+ tumors compared to other TNBCs (<i>p</i> = 0.0117). 31540486 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We observed a TNBC subtype switch from the luminal androgen receptor to the basal-like subtype at acquired resistance. 28555173 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. 29940524 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE A meta-analysis of public gene expression databases indicated that ACSL4 expression is positively correlated with a unique subtype of triple negative breast cancer (TNBC), characterized by the absence of androgen receptor (AR) and therefore referred to as quadruple negative breast cancer (QNBC). 24155918 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We demonstrate that AR agonist DHT induces MSL TNBC breast cancer cells proliferation and inhibits apoptosis in vitro. 26938985 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE HER2<sup>+</sup> and triple-negative breast cancer cell lines were treated with AR antagonist plus anti-HER2 mAb trastuzumab or mTOR inhibitor everolimus. 28468774 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. 28512248 2017